Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in ...

Hannah Abrams, MD, discusses the key takeaways of research into nonmedical barriers to HCT and CAR T therapy. Research led by Hannah Abrams, MD, fellow in hematolog-oncology at Fred Hutch Cancer ...

Hannah Abrams, MD, discusses the background behind research into nonmedical barriers to cell transplant and CAR T therapy.

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...